A

Adocia SA
PAR:ADOC

Watchlist Manager
Adocia SA
PAR:ADOC
Watchlist
Price: 6.57 EUR 1.86% Market Closed
Market Cap: 120.3m EUR
Section:
 

Relative Value

The Relative Value of one ADOC stock under the Base Case scenario is 5.74 EUR. Compared to the current market price of 6.57 EUR, Adocia SA is Overvalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ADOC Relative Value
Base Case
5.74 EUR
Overvaluation 13%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

11.4
P/S
P/S
Price to Sales
11.4
vs History
65
vs Industry
12
Median 3Y
12.4
Median 5Y
22.4
Industry
7.8
Forward
3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-4.9
Industry
24.1
Forward
10.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-7.1
Median 5Y
-3.4
Industry
21.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-4.4
Industry
23.8
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-17
Median 5Y
-8.9
Industry
3.3
More Details
11.4
EV/S
EV/S
Enterprise Value to Sales
11.4
vs History
65
vs Industry
9
Median 3Y
13.1
Median 5Y
26.8
Industry
8
Forward
3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
12
Median 3Y
0
Median 5Y
0
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-10
Median 5Y
-8.6
Industry
6.3
Forward
6.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-7.8
Industry
6.7
Forward
10.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-3.7
Industry
7.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-7.3
Median 5Y
-3.6
Industry
6.3
More Details
6.6
EV/IC
EV/IC
Enterprise Value to IC
6.6
vs History
46
vs Industry
24
Median 3Y
8
Median 5Y
6.1
Industry
5.5
More Details

Multiples Across Competitors

ADOC Competitors Multiples
Adocia SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Adocia SA
PAR:ADOC
118.3m EUR 11.4 -12.2 -16 -14.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 861 489.7 -160 938.6 -195 430.8 -193 200.7
US
Abbvie Inc
NYSE:ABBV
400.9B USD 6.7 170.7 16.5 23.4
US
Amgen Inc
NASDAQ:AMGN
176.1B USD 4.9 25.1 18.1 18.1
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD 5.3 19 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 9.9 31.5 23.1 24.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 080.5 -530.9 -578.1 -562.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD 5.7 17.7 16.8 19.1
AU
CSL Ltd
ASX:CSL
85.7B AUD 3.6 18.9 12.7 15.9
NL
argenx SE
XBRU:ARGX
45B EUR 14.6 34.4 59.4 61
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.8 159.1 192.9
P/S Multiple
Revenue Growth P/S to Growth
FR
A
Adocia SA
PAR:ADOC
Average P/S: 3 078 513.5
11.4
3%
3.8
FR
Pharnext SCA
OTC:PNEXF
33 861 489.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 080.5
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
14.6
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
P/E Multiple
Earnings Growth PEG
FR
A
Adocia SA
PAR:ADOC
Average P/E: 191
Negative Multiple: -12.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 938.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
A
Adocia SA
PAR:ADOC
Average EV/EBITDA: 39.8
Negative Multiple: -16 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 430.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.5
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.1
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
11%
1.5
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
59.4
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
159.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
A
Adocia SA
PAR:ADOC
Average EV/EBIT: 45.9
Negative Multiple: -14.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 200.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
61
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
192.9
N/A N/A

See Also

Summary
ADOC intrinsic value, competitors valuation, and company profile.
DCF Valuation
ADOC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ADOC stock valuation using valuation multiples.
Wall Street Estimates
ADOC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ADOC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.